SCHEMBL4282219

SCHEMBL4282219

Cc1nc2cc(OCC[C@@H]3CN(C(=O)O)CCN3C(=O)O)ccc2o1

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 5/20 0.38
LMNA P02545 1/20 0.38
KDM4E B2RXH2 1/20 0.38
HPGD P15428 1/20 0.38
HSD17B10 Q99714 1/20 0.38
ACACB O00763 1/20 0.38
FAAH O00519 1/20 0.37
DRD2 P14416 1/20 0.35
HRH3 Q9Y5N1 1/20 0.35
CHRNA7 P36544 1/20 0.35
NPC1 O15118 4/20 0.34
L3MBTL1 Q9Y468 2/20 0.34
STAT1 P42224 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
EPHX2 P34913 1/20 0.34
POLB P06746 1/20 0.34
S1PR1 P21453 2/20 0.33
GAA P10253 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4289498 0.92 TLR7 (0.39) HRH3CHRNA7
SCHEMBL4285430 0.89 GAA (0.42) RAB9ANPC1GAA
SCHEMBL4293911 0.87 POLB (0.44) LMNASMN1; SMN2POLB
SCHEMBL4294076 0.82 SIGMAR1 (0.39) RAB9ALMNAKDM4EHPGDHSD17B10
SCHEMBL4285120 0.81 NPC1 (0.39) RAB9ANPC1POLBGAA
SCHEMBL4291179 0.81 KDM4E (0.44) RAB9ALMNAKDM4EHPGDHSD17B10
SCHEMBL4291204 0.81 MAPT (0.48) RAB9ALMNAKDM4EHSD17B10HRH3
SCHEMBL4287203 0.81 CYP3A4 (0.41) RAB9ANPC1SMN1; SMN2
SCHEMBL4290172 0.80 GPR183 (0.46) RAB9AKDM4EHPGDDRD2HRH3
SCHEMBL4287782 0.80

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090227560-A1 Substituted imidazole compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-09-10 US disclosed
US-20090156612-A1 Substituted imidazole compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-06-18 US disclosed
WO-2008139941-A1 SUBSTITUTED IMIDAZOLE COMPOUND AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-11-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156612-A1 Substituted imidazole compound and use thereof REN, ACE, AGT RAB9A 1247/4885LMNA 1785/4885KDM4E 760/4885
US-20090227560-A1 Substituted imidazole compound and use thereof REN, ACE, AGT RAB9A 1247/4885LMNA 1785/4885KDM4E 760/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.